EUVIMEDEUVIMED entdecken
Crossref

The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?

Receptors & Clinical Investigation · 2016

DOI: 10.14800/rci.1163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Receptors & Clinical Investigation, 2016.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2016). The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?. Receptors & Clinical Investigation. https://doi.org/10.14800/rci.1163

Vancouver

The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?. Receptors & Clinical Investigation. 2016. doi:10.14800/rci.1163

BibTeX
@article{euvimed2016,
  title = {The antagonist SPECT tracer 123I-iododexetimide binds preferentially to the muscarinic M1 receptor in-vivo, but is it also a potential tool to assess the occupancy of muscarinic M1 receptors by agonists?},
  journal = {Receptors & Clinical Investigation},
  year = {2016},
  doi = {10.14800/rci.1163}
}
Kostenlos starten →